NasdaqGS:TARSPharmaceuticals
Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives
Tarsus Pharmaceuticals (TARS) opened 2026 with Q1 revenue of US$162.1 million and a basic EPS loss of US$0.16, alongside a trailing twelve month revenue base of US$535.1 million and a net loss of US$48.3 million. Over recent quarters the company has seen quarterly revenue move from US$66.4 million in Q4 2024 to US$78.3 million in Q1 2025 and then to US$162.1 million in Q1 2026. Basic EPS losses over the same snapshots were US$0.60, US$0.64 and US$0.16 respectively, highlighting a narrative...